Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints
Submitted by MedicalReplies on Tuesday, 15 December 2009No Comment
Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo…
See the rest here:
Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints
Leave your response!